{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:30:15Z","timestamp":1787020215806,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chongqing Municipal Health Commission Foundation","award":["No. 2023WSJK043"],"award-info":[{"award-number":["No. 2023WSJK043"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["No.2022M710555"],"award-info":[{"award-number":["No.2022M710555"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Program for Youth Innovation in Future Medicine of Chongqing Medical University","award":["No. W0172"],"award-info":[{"award-number":["No. W0172"]}]},{"name":"Science and Technology Innovation Medical Development Foundation of Beijing","award":["No. KC2021-JX-0186-11"],"award-info":[{"award-number":["No. KC2021-JX-0186-11"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13478-5","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:16:38Z","timestamp":1736986598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Characterization of the genomic landscape in liver oligometastatic NSCLC"],"prefix":"10.1186","volume":"25","author":[{"given":"Rongxin","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangming","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangzhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaicheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhou","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"13478_CR1","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/j.jtho.2018.07.017","volume":"13","author":"MC Roach","year":"2018","unstructured":"Roach MC, et al. Stereotactic body Radiation Therapy for Central Early-Stage NSCLC: results of a prospective phase I\/II trial. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2018;13:1727\u201332. https:\/\/doi.org\/10.1016\/j.jtho.2018.07.017.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"key":"13478_CR2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","volume":"28","author":"PE Postmus","year":"2017","unstructured":"Postmus PE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Annals Oncology: Official J Eur Soc Med Oncol. 2017;28:iv1\u201321. https:\/\/doi.org\/10.1093\/annonc\/mdx222.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"key":"13478_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"M Riihim\u00e4ki","year":"2014","unstructured":"Riihim\u00e4ki M, et al. Metastatic sites and survival in lung cancer. Lung cancer (Amsterdam Netherlands). 2014;86:78\u201384. https:\/\/doi.org\/10.1016\/j.lungcan.2014.07.020.","journal-title":"Lung cancer (Amsterdam Netherlands)"},{"key":"13478_CR4","doi-asserted-by":"publisher","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","volume":"4","author":"P Iyengar","year":"2018","unstructured":"Iyengar P, et al. Consolidative Radiotherapy for Limited Metastatic Non-small-cell Lung Cancer: a phase 2 Randomized Clinical Trial. JAMA Oncol. 2018;4:e173501. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3501.","journal-title":"JAMA Oncol"},{"key":"13478_CR5","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/jco.19.00201","volume":"37","author":"DR Gomez","year":"2019","unstructured":"Gomez DR, et al. Local consolidative therapy Vs. maintenance Therapy or Observation for patients with Oligometastatic Non-small-cell Lung Cancer: long-term results of a multi-institutional, phase II, Randomized Study. J Clin Oncology: Official J Am Soc Clin Oncol. 2019;37:1558\u201365. https:\/\/doi.org\/10.1200\/jco.19.00201.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"13478_CR6","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","volume":"5","author":"JM Bauml","year":"2019","unstructured":"Bauml JM, et al. Pembrolizumab after Completion of locally ablative therapy for Oligometastatic Non-small Cell Lung Cancer: a phase 2 trial. JAMA Oncol. 2019;5:1283\u201390. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1449.","journal-title":"JAMA Oncol"},{"key":"13478_CR7","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.Cd-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha D, et al. Tumor Mutational Burden as a predictive biomarker in solid tumors. Cancer Discov. 2020;10:1808\u201325. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-0522.","journal-title":"Cancer Discov"},{"key":"13478_CR8","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinf (Oxford England). 2009;25:1754\u201360. https:\/\/doi.org\/10.1093\/bioinformatics\/btp324.","journal-title":"Bioinf (Oxford England)"},{"key":"13478_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis K, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213\u20139. https:\/\/doi.org\/10.1038\/nbt.2514.","journal-title":"Nat Biotechnol"},{"key":"13478_CR10","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, et al. The genome analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297\u2013303. https:\/\/doi.org\/10.1101\/gr.107524.110.","journal-title":"Genome Res"},{"key":"13478_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson JT, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29:24\u20136. https:\/\/doi.org\/10.1038\/nbt.1754.","journal-title":"Nat Biotechnol"},{"key":"13478_CR12","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164. https:\/\/doi.org\/10.1093\/nar\/gkq603.","journal-title":"Nucleic Acids Res"},{"key":"13478_CR13","doi-asserted-by":"publisher","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","volume":"45","author":"SA Forbes","year":"2017","unstructured":"Forbes SA, et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017;45:D777\u201383. https:\/\/doi.org\/10.1093\/nar\/gkw1121.","journal-title":"Nucleic Acids Res"},{"key":"13478_CR14","doi-asserted-by":"publisher","unstructured":"Blokzijl F, Janssen R, van Boxtel R, Cuppen E. MutationalPatterns: comprehensive genome-wide analysis of mutational processes. Genome Med. 2018;10. https:\/\/doi.org\/10.1186\/s13073-018-0539-0.","DOI":"10.1186\/s13073-018-0539-0"},{"key":"13478_CR15","doi-asserted-by":"publisher","unstructured":"Chakravarty D et al. OncoKB: A Precision Oncology Knowledge Base. JCO precision oncology 2017, https:\/\/doi.org\/10.1200\/po.17.00011 (2017).","DOI":"10.1200\/po.17.00011"},{"key":"13478_CR16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284\u20137. https:\/\/doi.org\/10.1089\/omi.2011.0118.","journal-title":"OMICS"},{"key":"13478_CR17","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1158\/1078-0432.Ccr-16-0966","volume":"23","author":"M Canale","year":"2017","unstructured":"Canale M, et al. Impact of TP53 mutations on Outcome in EGFR-Mutated patients treated with first-line tyrosine kinase inhibitors. Clin cancer Research: Official J Am Association Cancer Res. 2017;23:2195\u2013202. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-0966.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"key":"13478_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jtho.2018.10.150","volume":"14","author":"Y Kim","year":"2019","unstructured":"Kim Y, et al. Concurrent genetic alterations predict the progression to Target Therapy in EGFR-Mutated Advanced NSCLC. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2019;14:193\u2013202. https:\/\/doi.org\/10.1016\/j.jtho.2018.10.150.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"key":"13478_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lungcan.2017.06.014","volume":"111","author":"C Labb\u00e9","year":"2017","unstructured":"Labb\u00e9 C, et al. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Lung cancer (Amsterdam Netherlands). 2017;111:23\u20139. https:\/\/doi.org\/10.1016\/j.lungcan.2017.06.014.","journal-title":"Lung cancer (Amsterdam Netherlands)"},{"key":"13478_CR20","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1158\/2159-8290.Cd-20-1863","volume":"11","author":"A Quintanal-Villalonga","year":"2021","unstructured":"Quintanal-Villalonga A, et al. Multiomic analysis of lung tumors defines pathways activated in Neuroendocrine Transformation. Cancer Discov. 2021;11:3028\u201347. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-1863.","journal-title":"Cancer Discov"},{"key":"13478_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41586-019-1004-y","volume":"567","author":"JW Lee","year":"2019","unstructured":"Lee JW, et al. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature. 2019;567:249\u201352. https:\/\/doi.org\/10.1038\/s41586-019-1004-y.","journal-title":"Nature"},{"key":"13478_CR22","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/jco.2016.71.9096","volume":"35","author":"JK Lee","year":"2017","unstructured":"Lee JK, et al. Clonal history and genetic predictors of Transformation Into Small-Cell Carcinomas from Lung Adenocarcinomas. J Clin Oncology: Official J Am Soc Clin Oncol. 2017;35:3065\u201374. https:\/\/doi.org\/10.1200\/jco.2016.71.9096.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"13478_CR23","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","volume":"14","author":"M Offin","year":"2019","unstructured":"Offin M, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-Mutant Lung cancers at risk for histologic Transformation and Inferior Clinical outcomes. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2019;14:1784\u201393. https:\/\/doi.org\/10.1016\/j.jtho.2019.06.002.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"key":"13478_CR24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrc3775","volume":"14","author":"Z Chen","year":"2014","unstructured":"Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14:535\u201346. https:\/\/doi.org\/10.1038\/nrc3775.","journal-title":"Nat Rev Cancer"},{"key":"13478_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu J, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021;27:152\u201364. https:\/\/doi.org\/10.1038\/s41591-020-1131-x.","journal-title":"Nat Med"},{"key":"13478_CR26","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1002\/ijc.31962","volume":"144","author":"T Jiang","year":"2019","unstructured":"Jiang T, et al. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases. Int J Cancer. 2019;144:2605\u201312. https:\/\/doi.org\/10.1002\/ijc.31962.","journal-title":"Int J Cancer"},{"key":"13478_CR27","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00270-020-02456-y","volume":"43","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, et al. Systemic therapy plus thermal ablation Versus systemic therapy alone for Oligometastatic Liver metastases from Non-small Cell Lung Cancer. Cardiovasc Interv Radiol. 2020;43:1285\u201393. https:\/\/doi.org\/10.1007\/s00270-020-02456-y.","journal-title":"Cardiovasc Interv Radiol"},{"key":"13478_CR28","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/j.jtho.2019.05.037","volume":"14","author":"N Giaj-Levra","year":"2019","unstructured":"Giaj-Levra N, et al. Defining Synchronous Oligometastatic Non-small Cell Lung Cancer: a systematic review. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2019;14:2053\u201361. https:\/\/doi.org\/10.1016\/j.jtho.2019.05.037.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"key":"13478_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.6004\/jnccn.2021.7117","volume":"20","author":"JY Chang","year":"2022","unstructured":"Chang JY, Verma V. Optimize local therapy for Oligometastatic and Oligoprogressive Non-small Cell Lung Cancer to Enhance Survival. J Natl Compr Cancer Network: JNCCN. 2022;20:531\u20139. https:\/\/doi.org\/10.6004\/jnccn.2021.7117.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"key":"13478_CR30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","volume":"17","author":"\u00c1 Quintanal-Villalonga","year":"2020","unstructured":"Quintanal-Villalonga \u00c1, et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol. 2020;17:360\u201371. https:\/\/doi.org\/10.1038\/s41571-020-0340-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"13478_CR31","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.annonc.2022.09.151","volume":"33","author":"P Selenica","year":"2022","unstructured":"Selenica P, et al. APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas. Annals Oncology: Official J Eur Soc Med Oncol. 2022;33:1284\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2022.09.151.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"key":"13478_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13046-023-02606-3","volume":"42","author":"N Yu","year":"2023","unstructured":"Yu N, et al. Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer. J Experimental Clin cancer Research: CR. 2023;42:37. https:\/\/doi.org\/10.1186\/s13046-023-02606-3.","journal-title":"J Experimental Clin cancer Research: CR"},{"key":"13478_CR33","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jtho.2016.02.002","volume":"11","author":"X Ma","year":"2016","unstructured":"Ma X, et al. Prognostic and predictive effect of TP53 mutations in patients with Non-small Cell Lung Cancer from Adjuvant Cisplatin-based therapy randomized trials: a LACE-Bio pooled analysis. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2016;11:850\u201361. https:\/\/doi.org\/10.1016\/j.jtho.2016.02.002.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"key":"13478_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41586-023-06303-1","volume":"620","author":"H Isozaki","year":"2023","unstructured":"Isozaki H, et al. Therapy-induced APOBEC3A drives evolution of persistent cancer cells. Nature. 2023;620:393\u2013401. https:\/\/doi.org\/10.1038\/s41586-023-06303-1.","journal-title":"Nature"},{"key":"13478_CR35","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1158\/0008-5472.Can-16-3394","volume":"77","author":"AM Green","year":"2017","unstructured":"Green AM, et al. Cytosine deaminase APOBEC3A sensitizes leukemia cells to inhibition of the DNA replication checkpoint. Cancer Res. 2017;77:4579\u201388. https:\/\/doi.org\/10.1158\/0008-5472.Can-16-3394.","journal-title":"Cancer Res"},{"key":"13478_CR36","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1158\/0008-5472.Can-16-3389","volume":"77","author":"R Buisson","year":"2017","unstructured":"Buisson R, Lawrence MS, Benes CH, Zou L. APOBEC3A and APOBEC3B activities render Cancer cells susceptible to ATR inhibition. Cancer Res. 2017;77:4567\u201378. https:\/\/doi.org\/10.1158\/0008-5472.Can-16-3389.","journal-title":"Cancer Res"},{"key":"13478_CR37","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.ccell.2021.07.006","volume":"39","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, et al. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell. 2021;39:1245\u2013e12611246. https:\/\/doi.org\/10.1016\/j.ccell.2021.07.006.","journal-title":"Cancer Cell"},{"key":"13478_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.18.00376","volume":"3","author":"MK Stein","year":"2019","unstructured":"Stein MK, et al. Tumor Mutational Burden is Site Specific in Non-small-cell Lung Cancer and is highest in Lung Adenocarcinoma Brain metastases. JCO Precision Oncol. 2019;3:1\u201313. https:\/\/doi.org\/10.1200\/po.18.00376.","journal-title":"JCO Precision Oncol"},{"key":"13478_CR39","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1158\/1078-0432.Ccr-20-1825","volume":"26","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, et al. The genomic Landscape of SMARCA4 alterations and associations with outcomes in patients with Lung Cancer. Clin cancer Research: Official J Am Association Cancer Res. 2020;26:5701\u20138. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-1825.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"key":"13478_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2014.07.018","volume":"26","author":"KC Helming","year":"2014","unstructured":"Helming KC, Wang X, Roberts CWM. Vulnerabilities of mutant SWI\/SNF complexes in cancer. Cancer Cell. 2014;26:309\u201317. https:\/\/doi.org\/10.1016\/j.ccr.2014.07.018.","journal-title":"Cancer Cell"},{"key":"13478_CR41","doi-asserted-by":"publisher","first-page":"31572","DOI":"10.18632\/oncotarget.25803","volume":"9","author":"E Haines","year":"2018","unstructured":"Haines E, et al. Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer. Oncotarget. 2018;9:31572\u201389. https:\/\/doi.org\/10.18632\/oncotarget.25803.","journal-title":"Oncotarget"},{"key":"13478_CR42","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12916-021-02089-z","volume":"19","author":"S Zhao","year":"2021","unstructured":"Zhao S, et al. Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer. BMC Med. 2021;19:223. https:\/\/doi.org\/10.1186\/s12916-021-02089-z.","journal-title":"BMC Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13478-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13478-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13478-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T11:42:57Z","timestamp":1737027777000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13478-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13478"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13478-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethical committee of Chongqing Medical University approved the study and all methods were also performed in accordance with the relevant guidelines and regulations under the committee supervision. Written informed consent was obtained from each participant prior to enrollment. Clinical trial number: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}